<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188343</url>
  </required_header>
  <id_info>
    <org_study_id>JEC04</org_study_id>
    <secondary_id>UTN: U1111-1112-2143</secondary_id>
    <nct_id>NCT01188343</nct_id>
  </id_info>
  <brief_title>Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers</brief_title>
  <official_title>Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus
      vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at
      separate visits 6 weeks apart in toddlers aged 12 to 18 months.

      Primary objective:

        -  To demonstrate the non-inferiority of the antibody responses in terms of seroconversion
           of the concomitant administration of JE-CV and MMR compared to the antibody responses
           after the single administration of JE-CV and MMR vaccine.

      Secondary objectives:

        -  To describe the immune response to JE CV and MMR before and after one dose of JE CV and
           MMR vaccine, respectively.

        -  To describe the safety of a single dose of JE-CV and MMR vaccine (given separately at a
           6-week interval and the safety of the concomitant administration of JE-CV and MMR
           vaccine in all subjects up to 6 months after last vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive Japanese encephalitis chimeric virus vaccine and
      measles-mumps-rubella vaccine and will be monitored for safety throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 42 post-vaccination</time_frame>
    <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion to JE-CV and MMR Antigens Before and 42 Days Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</measure>
    <time_frame>Pre-vaccination and Day 42 post-vaccination</time_frame>
    <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection to JE-CV and MMR Antigens Before, at Month 6 After Last Vaccination and Month 12 After First Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</measure>
    <time_frame>Pre-vaccination and up to Month 12 post-vaccination</time_frame>
    <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroprotection was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 (1/dil) and post-vaccination titer ≥1/10, (1/dil) or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 units/ml when pre-vaccination titer is &lt;10 units/ml; and for Rubella, post-vaccination titer ≥1/10 IU/ml when pre-vaccination titer is &lt;10 IU/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies to Vaccine Antigens Before and After Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</measure>
    <time_frame>Pre-vaccination and Day 42 post-vaccination</time_frame>
    <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of JE-CV Vaccine</measure>
    <time_frame>Day 0 up to Day14 post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of MMR Vaccine</measure>
    <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
    <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serological Status of Flavivirus at Before (Baseline) Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination)</time_frame>
    <description>Neutralizing antibodies levels against dengue were only evaluated on subjects ELISA positive for Immunoglobulin G (IgG) or Immunoglobulin M (IgM). Flavivirus positive was defined as antibodies against JE-CV virus ≥10 (l/dil) or antibodies against at least one dengue virus serotype ≥10 (l/dil); Flavivirus negative was defined as antibodies against JE CV virus &lt; 10 (l/dil) and antibodies against the 4 dengue virus serotypes &lt; 10 (l/dil).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">542</enrollment>
  <condition>Japanese Encephalitis</condition>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus</intervention_name>
    <description>0.5 mL each; Subcutaneous (SC)</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>JE-CV</other_name>
    <other_name>MMR II®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus</intervention_name>
    <description>0.5 mL each, Subcutaneous (SC)</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>JE-CV</other_name>
    <other_name>MMR II®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus</intervention_name>
    <description>0.5 mL each, subcutaneous (SC)</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>JE-CV</other_name>
    <other_name>MMR II®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Aged 12 to 18 months on the day of inclusion .

          -  Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg.

          -  Subject in good health based on medical history and physical examination.

          -  Provision of informed consent form signed by at least one parent or other legally
             acceptable representative, and by an independent witness if the parents or legally
             acceptable representative cannot read.

          -  Subject and parent/legally acceptable representative or delegate able to attend all
             scheduled visits and comply with all trial procedures.

        Exclusion Criteria

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding the first trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination except for
             pandemic influenza vaccination, which may be received at least two weeks before the
             study vaccines.

          -  Planned receipt of any vaccine up to the 6 weeks following the last trial vaccination
             except for pandemic influenza vaccine. In the event of a local or national
             immunization program with a pandemic influenza vaccine, participants who receive a
             pandemic influenza vaccine at any time during the trial will not be withdrawn from the
             trial.

          -  Previous vaccination against measles, measles-mumps-rubella (MMR), or flavivirus
             disease, including Japanese encephalitis (JE).

          -  Receipt of blood in the past 6 months that might interfere with the assessment of the
             immune response

          -  Receipt of intravenous injection of plasma, platelet product, or high dose of
             intravenous immunoglobulin in the past 11 months

          -  Receipt of intramuscular treatment of immunoglobulin or Hepatitis B immunoglobulin in
             the past 3 months

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy.

          -  Known history of human immunodeficiency virus, hepatitis B surface antigen, or
             hepatitis C seropositivity.

          -  History of measles, mumps, rubella, or flavivirus infection confirmed either
             clinically, serologically, or microbiologically.

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to a vaccine containing any of the same substances .

          -  Known systemic hypersensitivity to gelatin, eggs, or anaphylactic/anaphylactoid
             reaction to neomycin.

          -  Known history of thrombocytopenia.

          -  Administration of any anti-viral within 2 months preceding first vaccination and up to
             the 6 weeks following the last trial vaccination.

          -  History of central nervous system disorder or disease, including seizures and febrile
             seizures.

          -  Chronic illness at a stage that could interfere with trial conduct or completion, in
             the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Japanese encephalitis chimeric virus vaccine</keyword>
  <keyword>Measles</keyword>
  <keyword>Mumps</keyword>
  <keyword>Rubella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 14 August 2010 through 28 July 2011 at 5 clinic centers in Taiwan.</recruitment_details>
      <pre_assignment_details>A total of 550 participants who met all of the inclusion and none of the exclusion criteria were randomized, 542 were vaccinated and reported.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JE CV + MMR (Group 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
        </group>
        <group group_id="P2">
          <title>MMR + JE CV (Group 2)</title>
          <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
        </group>
        <group group_id="P3">
          <title>JE CV/MMR (Group 3)</title>
          <description>Participants 12 to 18 months of age received one dose each of MMR and JE CV vaccine on day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JE CV + MMR (Group 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
        </group>
        <group group_id="B2">
          <title>MMR + JE CV (Group 2)</title>
          <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
        </group>
        <group group_id="B3">
          <title>JE CV/MMR (Group 3)</title>
          <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="219"/>
            <count group_id="B3" value="221"/>
            <count group_id="B4" value="542"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.1" spread="1.12"/>
                    <measurement group_id="B2" value="13.0" spread="1.08"/>
                    <measurement group_id="B3" value="13.1" spread="1.19"/>
                    <measurement group_id="B4" value="13.1" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="221"/>
                    <measurement group_id="B4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination</title>
        <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 42 post-vaccination</time_frame>
        <population>Seroconversion was assessed in the Per Protocol Analysis Set with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE-CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE-CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination</title>
          <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml.</description>
          <population>Seroconversion was assessed in the Per Protocol Analysis Set with evaluable data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV (N = 95, 0, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">JE-CV was not administered on Day 0 in this group</measurement>
                    <measurement group_id="O3" value="96.9" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles (N = 0, 170, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">MMR was not administered on Day 0 in this group.</measurement>
                    <measurement group_id="O2" value="97.6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="100" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps (N = 0, 173, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">MMR was not administered on Day 0 in this group.</measurement>
                    <measurement group_id="O2" value="98.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella (N = 0, 154, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">MMR was not administered on Day 0 in this group.</measurement>
                    <measurement group_id="O2" value="99.4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99.4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion to JE-CV and MMR Antigens Before and 42 Days Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
        <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/m</description>
        <time_frame>Pre-vaccination and Day 42 post-vaccination</time_frame>
        <population>Seroconversion to JE-CV and to MMR vaccine antigen was assessed in all participants who were randomized, vaccinated, who performed all protocol defined activities and has evaluable data (Per-protocol Analysis Set).</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE-CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE-CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to JE-CV and MMR Antigens Before and 42 Days Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
          <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroconversion was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 and post-vaccination titer ≥1/10, or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/ml; and for Rubella, post-vaccination titer ≥1/10 U/ml when pre-vaccination titer is &lt;10 U/m</description>
          <population>Seroconversion to JE-CV and to MMR vaccine antigen was assessed in all participants who were randomized, vaccinated, who performed all protocol defined activities and has evaluable data (Per-protocol Analysis Set).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV Pre-vaccination (N = 95, 158, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV Post-vaccination (N = 95, 158, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="96.9" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles Pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles Post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9"/>
                    <measurement group_id="O2" value="97.7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps Pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps Post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="98.9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella Pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="11.9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="8.7" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella Post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection to JE-CV and MMR Antigens Before, at Month 6 After Last Vaccination and Month 12 After First Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
        <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroprotection was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 (1/dil) and post-vaccination titer ≥1/10, (1/dil) or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 units/ml when pre-vaccination titer is &lt;10 units/ml; and for Rubella, post-vaccination titer ≥1/10 IU/ml when pre-vaccination titer is &lt;10 IU/m</description>
        <time_frame>Pre-vaccination and up to Month 12 post-vaccination</time_frame>
        <population>Seroprotection to JE-CV and to MMR vaccine antigen was assessed in all participants who were randomized, vaccinated and who performed all protocol defined activities the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE-CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE-CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE-CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE-CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection to JE-CV and MMR Antigens Before, at Month 6 After Last Vaccination and Month 12 After First Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
          <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA). Seroprotection was defined as: for JE-CV - participants with a pre-vaccination titer &lt;1/10 (1/dil) and post-vaccination titer ≥1/10, (1/dil) or a pre-vaccination titer ≥1/10 and 4-fold increase from pre- to post; for Measles - post-vaccination titer ≥120 mIU/ml, when pre-vaccination titer is &lt;120 mIU/ml; for Mumps - post-vaccination titer ≥1/10 units/ml when pre-vaccination titer is &lt;10 units/ml; and for Rubella, post-vaccination titer ≥1/10 IU/ml when pre-vaccination titer is &lt;10 IU/m</description>
          <population>Seroprotection to JE-CV and to MMR vaccine antigen was assessed in all participants who were randomized, vaccinated and who performed all protocol defined activities the Full Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV Pre-vaccination (N=102, 197, 221)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV 6 months Post-vaccination (N=96, 191, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV 12 months Post-vaccination (N=89, 164, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles Pre-vaccination (N = 101, 217, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles 6 months Post-vaccination (N=96, 191, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles 12 months Post-vaccination (N=89, 164, 193</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps Pre-vaccination (N=101, 217, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps 6 months Post-vaccination (N=96, 191, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps 12 months Post-vaccination (N=89, 164, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella Pre-vaccination (N=101, 217, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella 6 months Post-vaccination (N=96, 191, 217)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella 12 months Post-vaccination (N=89, 164, 193</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies to Vaccine Antigens Before and After Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
        <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA).</description>
        <time_frame>Pre-vaccination and Day 42 post-vaccination</time_frame>
        <population>Geometric mean titers were assessed in the Per Protocol Analysis Set population with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies to Vaccine Antigens Before and After Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
          <description>JE-CV antigens were measured using a 50% plaque reduction neutralization test (PRNT50); MMR antigens were measured using enzyme linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean titers were assessed in the Per Protocol Analysis Set population with evaluable data.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV pre-vaccination (N = 95, 158, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="5.00" lower_limit="5.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE-CV post-vaccination (N = 95, 158, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510" lower_limit="356" upper_limit="731"/>
                    <measurement group_id="O2" value="581" lower_limit="449" upper_limit="752"/>
                    <measurement group_id="O3" value="332" lower_limit="258" upper_limit="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="31.5" upper_limit="37.3"/>
                    <measurement group_id="O2" value="33.4" lower_limit="31.4" upper_limit="35.5"/>
                    <measurement group_id="O3" value="33.4" lower_limit="32.0" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measles post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1835" lower_limit="1536" upper_limit="2193"/>
                    <measurement group_id="O2" value="1723" lower_limit="1506" upper_limit="1971"/>
                    <measurement group_id="O3" value="1924" lower_limit="1753" upper_limit="2111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="2.46" upper_limit="2.71"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.52" upper_limit="2.75"/>
                    <measurement group_id="O3" value="2.55" lower_limit="2.49" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mumps Post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="70.1" upper_limit="93.9"/>
                    <measurement group_id="O2" value="87.5" lower_limit="77.6" upper_limit="98.8"/>
                    <measurement group_id="O3" value="89.2" lower_limit="80.0" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella pre-vaccination (N = 94, 176, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" lower_limit="3.44" upper_limit="4.43"/>
                    <measurement group_id="O2" value="3.97" lower_limit="3.60" upper_limit="4.37"/>
                    <measurement group_id="O3" value="3.60" lower_limit="3.32" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rubella post-vaccination (N = 94, 176, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="68.3" upper_limit="89.2"/>
                    <measurement group_id="O2" value="81.4" lower_limit="73.7" upper_limit="89.9"/>
                    <measurement group_id="O3" value="69.6" lower_limit="63.6" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of JE-CV Vaccine</title>
        <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
        <time_frame>Day 0 up to Day14 post-vaccination</time_frame>
        <population>Solicited injection site and systemic events were assessed in all randomized and vaccinated participants, the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of JE-CV Vaccine</title>
          <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
          <population>Solicited injection site and systemic events were assessed in all randomized and vaccinated participants, the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="35" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Fever (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="35" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Vomiting (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="39" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Crying Abnormal (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="79" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Drowsiness (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="45" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="67" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Appetite Lost (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="46" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="78" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Irritability (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="39" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="72" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N = 102, 195, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serological Status of Flavivirus at Before (Baseline) Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
        <description>Neutralizing antibodies levels against dengue were only evaluated on subjects ELISA positive for Immunoglobulin G (IgG) or Immunoglobulin M (IgM). Flavivirus positive was defined as antibodies against JE-CV virus ≥10 (l/dil) or antibodies against at least one dengue virus serotype ≥10 (l/dil); Flavivirus negative was defined as antibodies against JE CV virus &lt; 10 (l/dil) and antibodies against the 4 dengue virus serotypes &lt; 10 (l/dil).</description>
        <time_frame>Day 0 (pre-vaccination)</time_frame>
        <population>Serological status of Flavivirus infection was assessed in the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Serological Status of Flavivirus at Before (Baseline) Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine</title>
          <description>Neutralizing antibodies levels against dengue were only evaluated on subjects ELISA positive for Immunoglobulin G (IgG) or Immunoglobulin M (IgM). Flavivirus positive was defined as antibodies against JE-CV virus ≥10 (l/dil) or antibodies against at least one dengue virus serotype ≥10 (l/dil); Flavivirus negative was defined as antibodies against JE CV virus &lt; 10 (l/dil) and antibodies against the 4 dengue virus serotypes &lt; 10 (l/dil).</description>
          <population>Serological status of Flavivirus infection was assessed in the Full Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JE-CV virus/dengue serotypes FV Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV virus/dengue serotypes FV Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="179" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="216" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE CV virus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any dengue serotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dengue serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of MMR Vaccine</title>
        <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
        <time_frame>Day 0 up to Day 14 post-vaccination</time_frame>
        <population>Solicited injection site and systemic events were assessed in all randomized and vaccinated participants, the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>JE CV + MMR (Group 1)</title>
            <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
          </group>
          <group group_id="O2">
            <title>MMR + JE CV (Group 2)</title>
            <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
          </group>
          <group group_id="O3">
            <title>JE CV/MMR (Group 3)</title>
            <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of MMR Vaccine</title>
          <description>Solicited injection site: Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Pain - Cries when injected limb is moved or movement of limb is reduced; Erythema and Swelling - ≥5 cm. Grade 3 systemic reactions: Fever - &gt;39.5°C; Vomiting - ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal - &gt;3 hours; Drowsiness - Sleeping most of the time or difficult to wake; Appetite Lost - Refused ≥3 feeds/meals or refused most feeds/meals; Irritability - Inconsolable.</description>
          <population>Solicited injection site and systemic events were assessed in all randomized and vaccinated participants, the Safety Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="36" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="22" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Fever (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N = 101, 211, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Vomiting (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="39" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Crying Abnormal (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="73" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="79" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Drowsiness (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="68" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="67" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Appetite Lost (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="80" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="78" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Irritability (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="64" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="72" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (N = 101, 210, 219)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to Day 28 post-vaccination.</time_frame>
      <desc>The total number (N) for solicited adverse events in the table reflects those participants for which the diary cards were returned and for which data were available for the event during the period.</desc>
      <group_list>
        <group group_id="E1">
          <title>JE CV + MMR (Group 1)</title>
          <description>Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE CV) on day 0 and one dose of Measles, Mumps, and Rubella (MMR) vaccine on day 42</description>
        </group>
        <group group_id="E2">
          <title>MMR + JE CV (Group 2)</title>
          <description>Participants 12 to 18 months of age received one dose of MMR vaccine on day 0 and one dose of JE CV vaccine on day 42</description>
        </group>
        <group group_id="E3">
          <title>JE CV/MMR (Group 3)</title>
          <description>Participants 12 to 18 months of age received one dose each of MMR and JE-CV vaccine on day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Diarrhea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Hand foot and mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="219"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="210"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="195"/>
                <counts group_id="E3" events="35" subjects_affected="35" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Injection site Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="195"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="195"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="211"/>
                <counts group_id="E3" events="53" subjects_affected="53" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite Lost</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="101"/>
                <counts group_id="E2" events="80" subjects_affected="80" subjects_at_risk="210"/>
                <counts group_id="E3" events="78" subjects_affected="78" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="102"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="196"/>
                <counts group_id="E3" events="67" subjects_affected="67" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E2" events="68" subjects_affected="68" subjects_at_risk="210"/>
                <counts group_id="E3" events="67" subjects_affected="67" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying Abnormal</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="101"/>
                <counts group_id="E2" events="73" subjects_affected="73" subjects_at_risk="210"/>
                <counts group_id="E3" events="79" subjects_affected="79" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="210"/>
                <counts group_id="E3" events="72" subjects_affected="72" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

